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Purpose: Effective routine monitoring and surveillance of parasite genes is a necessary
strategy in the control of parasites’ resistance to antimalarial drugs, according to the WHO’s
recommendation. This cross-sectional study therefore aimed at carrying out an epidemiolo-
gical analysis on malaria incidence in Ado-Odo/Ota, Ogun State.
Patients and methods: Blood and corresponding saliva samples were collected from
1,243 subjects of all ages and sex presenting with fever and a parasitemia level ≥2,000
between September 2016 and March 2018. Samples were collected from selected health
facilities in the study area of Ogun state to establish the prevalence of falciparum malaria and
determine resistance genes harbored by the parasites. The overall prevalence of falciparum
malaria in the study site by microscopic examination was 45.86%. The highest incidence of
57.42% was recorded among male subjects. Point mutations of K76T and N86Y in the
Pfcrt and pfmdr-1 genes, as well as non-synonymous mutations in Pfk13 genes, were
screened for and sequenced for further analysis.
Results: Pfcrt was detectable in 57.42% of blood and 51.02% of saliva samples, respec-
tively. About 34.78% of the subjects that were confirmed microscopically harbored the
Pfmdr-1 mutated gene while 26.67% of the saliva samples revealed Pfmdr-1.
Epidemiological studies identified the presence of wild-type Pfk13 genes in 21.84% of
blood and 44.44% of saliva samples correspondingly. For each of the genes evaluated, saliva
portrayed great diagnostic performance when compared with blood.
Conclusion: Findings from this study have established the prevalence of malaria and the
resistance pattern of P. falciparum in the study area. The findings may help in formulating
drug policies and suggest the use of saliva as a noninvasive point-of-care method of
diagnosing malaria potentially deployable to rural endemic areas.
Keywords: prevalence, resistance, malaria, Ado-Odo/Ota
Introduction
Malaria, the life-threatening vector-borne disease, remains a global threat and
a major public health issue across the world.1 About 219 million cases and
435,000 deaths from malaria occurred worldwide in 2017.2 A major factor hinder-
ing malaria elimination strategies is the continuous emergence of Plasmodium
falciparum parasites resistant to all known existing malaria drugs.3,4 However,
according to the WHO, malaria can be prevented and even cured, and amplified
efforts between the years 2000 and 2015 have considerably decreased the fatality
rate of malaria by 60%.1
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In retrospect to all intensified control methods against
malaria, drug resistance has remained on the rise, hence
posing a serious challenge where control and prevention
are concerned and increasing the need for vaccine
development.4 Antimalarial drug resistance may occur
due to variations in the build-up of drug or efflux mechan-
isms (as in the case of chloroquine, amodiaquine, quinine,
halofantrine, and mefloquine resistance) or due to dimin-
ished affinity of the drug’s target, which may result from
point mutations in the respective genes that encode these
targets (pyrimethamine, cycloguanil, sulphonamide, atova-
quone, and artemisinin resistance).5 Following the resis-
tance of Plasmodium falciparum to antimalarial drugs
such as chloroquine and sulfadoxine-pyrimethamine, the
WHO in 2001 endorsed artemisinin combination therapies
(ACTs) comprising drug combinations of artemether-
lumefantrine (AL) and amodiaquine-artesunate (AQ-AS)
as first-line treatment for uncomplicated malaria.4 The
efficacy of artemisinin combination drugs has been
proven,6 notwithstanding drug combinations have a lower
risk of resistance and may present greater problems if such
occurs.
All existing malaria diagnostic measures (eg, PCR,
microscopy, blood smear, and RDTs) involve the use of
blood through finger pricking or drawing with needle and
syringe. These invasive methods of malaria diagnosis are
not without discouraging factors such as pain associated
with needles, fear of contraction of an infectious disease
like HIV, high cost of diagnosis, traditional bias and so on,
hence leading to self-medication and eventually resistance.
Based on these, other sources of body fluid such as human
saliva are being explored to determine their potential as
a malaria diagnostic tool. This is crucial in the battle
against resistance in order to enhance the speedy detection
of parasites upon symptoms. Human saliva is already
being used to detect a broad band of diseases such as
cancers and cardiovascular diseases due to its constituents
of proteins, electrolytes, and DNA.7 Viral infections such
as HIV and human papillomavirus (HPV) have also been
detected using saliva diagnostics test kits.8,9 Some studies
have reported the detection of Plasmodium falciparum in
the saliva of infected subjects.10,11 Therefore, saliva may
be a more encouraging noninvasive substitute for malaria
diagnosis other than blood.12
Antimalarial drug resistance can be evaluated in vivo
and in vitro by parasite susceptibility or by the exploitation
of molecular methods such as PCR techniques to identify
genetic markers. Drug resistance can lead to the inability
to clear asexual parasites found in the peripheral blood,
which eventually develop into gametocytes, ie,
the transmission stage of the parasite genotype.5 PCR
methods are principally useful for findings on strain varia-
tion, mutations, and examination of parasite genes
involved in drug resistance. In the battle against malaria,
the identification of the gene responsible for chloroquine
resistance transporter (Pfcrt) brought about a scientific
revolution.13 Between the amino acids lysine and threo-
nine lie other polymorphic amino acids; however, a change
in the Pfcrt codon K76T gene presents as the most depend-
able genetic marker among them all and may be essential
for coding the resistance makeup.14–16 Notwithstanding,
chloroquine resistance could occur in mutations anywhere
between codons 72 and 76. P. falciparum multidrug resis-
tance (Pfmdr-1) occurs due to a substitution in codon
N86Y chromosome and is associated with drug resistance
to chloroquine, halofantrine, quinine, and mefloquine.
Some studies identified the association of single nucleotide
polymorphism (SNP) causing a base change from aspar-
agine to tyrosine at codon 86 (N86Y) with chloroquine
resistance both in vitro and in vivo.17–19
Existing malaria diagnostic methods using either rapid
diagnostic test (RDT) and/or microscopy require the use of
blood samples for effective diagnosis. Although these
approaches are sensitive, accurate, relatively cheaper and
rapid, their greatest disadvantage is their dependency on
blood samples for diagnosis due to the increased risks of
needle injuries and risk of accidental infection from dis-
eases which are common in malaria-endemic areas as well
as cultural blood taboos in certain African communities.
These serve as limitations, particularly in longitudinal
studies that require repeated testing and monitoring to be
conducted, as it reduces community participation.20
The use of body fluids such as saliva has been employed
as a diagnostic test fluid for determining immunity and
detecting diseases such as cancers, cardiovascular diseases,
HIV, etc.21–23 It is convenient to use for diagnosis as it is not
difficult to collect, noninvasive, and possesses minimal risk
of infection compared to blood collection. Saliva contains
a minimum of 400 proteins which interface with the salivary
glands and blood vessels, exchanging materials at
intervals.24,25 Diffusion and active transport of human
pathogens are therefore most likely to end up in the saliva,
hence presenting a reliable tool for disease diagnosis.7
Moreover, the reliability of PCR as a malaria detection
tool using saliva could be optimized and remains consis-
tently applicable across various populations.
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Artemisinin-based combination therapies recommended
by WHO are effective against Plasmodium parasites and
can curb the spread of resistance.26 However, the risk of
developing resistance to combined drugs is now evident
from Southeast Asia, where ACT resistance has now
emerged.27 As the parasite develops multi-drug resistance
to a previously active drug, it threatens malaria control in
endemic areas which largely depend on chemotherapy. The
quest to determine the presence of parasite resistance to
ACTs and other antimalarial drugs including artemisinin
and its derivatives which is the hallmark for treatment of
malaria, is the drive for carrying out this study and aimed at
determining the development of new methods for malaria
diagnosis. Notwithstanding important gains in fields of
research in malaria, its methods of diagnosis remain inva-
sive, with the drugs for treatment not available in many
rural communities, and if available may be taken in inap-
propriate doses, thus leading to further resistance.
Furthermore, effective monitoring of parasite-resistant
genes is necessary for determining the efficacy of currently
used regimens and deciding on the time point for introdu-
cing new drugs/re-introducing old drugs. It is also crucial in
the development of new diagnostic tools, such as saliva
body fluid, which will aid in curbing malaria transmission
as well as preventing resistance. Hence, this study is
focused on carrying out an epidemiological study on falci-
parum malaria infection in Ado-Odo/Ota, Ogun State,
Nigeria and determine the prospect using of saliva in detect-
ing P. falciparum markers of resistance.
Materials and methods
Infected human blood and corresponding saliva samples
were obtained from selected hospitals in the study site.
Males and females of different age ranges presenting with
fever and body temperature greater than 37°C were recruited
to the study. The study was conducted in accordance with
the Declaration of Helsinki, and ethical permission for this
study was approved by the Covenant University Biological
Sciences Ethical Review Committee (CUBIOSCREC) and
Covenant Health Research Ethics Committee (CHREC). All
research participants approved their informed consent and
minors were represented by their guardians. Inclusion cri-
teria included persons willing to complete and sign the
consent form and with significant parasitemia level of
≥2,000 parasites/µL of blood.
Thin and thick films of the blood samples were stained
with Giemsa stain. Blood films were examined microscopi-
cally using the 100× (oil immersion) objective lens. Qiagen
DNA extraction kit (Qiagen NV, Venlo, the Netherlands) was
used to extract Plasmodia DNA from the blood and saliva
samples. NanoDrop Spectrophotometer (Thermo Fisher
Scientific, Waltham, MA, USA) was used to check for
DNA concentration and purity using a ratio of 260/280.
Point mutations in the genes of Pfcrt and Pfmdr-1 were
analyzed using PCR/nested PCR-restriction fragment length
polymorphism (RFLP) methods,14 and used to amplify and
confirm the mutation of resistant genes. If any discrepancies
were found by different diagnostic methods, those
samples were excluded from the study. Afterward, the ampli-
cons were run electrophoretically on a gel to check for bands
size of the amplified resistance gene region.
The data obtained were analyzed using Microsoft
Excel. Statistical analysis was carried out using P-values
from a chi-square test for proportions using a P-value of
0.05, comparing the relationship between age and rate of
incidence of falciparum malaria. Values less than 0.05
were accepted as statistically significant. The analysis
was done using GraphPad Prism 6.0 (GraphPad
Software, Inc., La Jolla, CA, USA).
Results
The results of the epidemiological study of Plasmodium
falciparum infection in Ado-Odo/Ota Local Government
Area of Ogun State, Southwestern Nigeria in 1,243 sub-
jects are presented in Tables 1–5. The malaria incidence
detected by microscopy in 2017 was 52.09% with the
highest incidence of 55.38% among the age group ≤5
years (Table 1). Table 2 shows the incidence of malaria
among study subjects in 2018, with an overall incidence of
44.11%. Incidence was higher among males within the
same age range in this study. The overall prevalence of
falciparum malaria during the study period was 45.86%
(Table 3). There was a significant association between age
younger than 20 years and the incidence of malaria during
the study as shown in Table 4. The prevalence of the
different molecular markers screened from blood and
Table 1 Incidence of falciparum malaria in the study area (2017)
Samples collected Positive samples
Age (years) M F T M F T I (%)
≤5 32 38 70 17 24 41 58.57%
10–20 96 99 195 55 53 108 55.38%
≥20 68 74 142 25 38 63 44.37%
Total 196 211 407 97 115 212 52.09%
Abbreviations: M, males; T, total; F, females, I, incidence.
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corresponding saliva samples in the subjects are presented
in Table 5. Figure 1 shows the overall detection of malaria
in saliva and blood in all samples; these rates were similar.
Plates 1–5 show the band sizes of the amplified molecular
markers of antimalarial resistance on an agarose gel.
Discussion
A key instrument to successful management of the global
malaria challenge remains the WHO’s recommended con-
tinuous monitoring and effective surveillance of resistance
development in the parasites’ genes.27 This study presents
the epidemiology of falciparum malaria in Ado-Odo/Ota,
Ogun State, Nigeria, and surveillance for resistance mar-
kers using blood and saliva, a noninvasive sampling
method. In the relatively large samples evaluated in the
study area, malaria incidence was over 45% and increased
over the two-year period, which suggests that malaria
transmission is sustained in an era of malaria elimination.
Global reports on malaria control indicate stalled progress
in the successful reduction of malaria transmission, espe-
cially for Nigeria, which has the highest burden of malaria
cases globally and in Africa, followed by Madagascar and
the Democratic Republic of the Congo, where increases in
malaria rates from 2016 to 2017 were recorded.28 Our
findings lend support to this and further suggest that this
increasing trend appears to continue into 2018.
The incidence of falciparum malaria following micro-
scopy in 2017 was 52.09% with the highest rate of 55.38%
among the age range 10–20 years (Table 1). Table 2 shows
the incidence of malaria among study subjects in 2018,
with an incidence of 44.11%. It was observed that inci-
dence was higher among males within this age range in
this study. The reason for this may be factors such as
habits and lifestyles associated with males within that
age bracket, some of which may include negligence in
the intermittentuseof bed nets, greater exposure to mos-
quito bites from play areas and drugs misuse. Females on
the other hand exhibit carefulness in these areas. Age was
also shown to be a risk factor for malaria,1 as the incidence
of falciparum malaria considerably increased with age.
The overall prevalence of falciparum malaria during the
study period was 45.86% (Table 3). The incidence in 2018
and overall prevalence show that there is a significant
association between age and incidence of malaria in the
study as shown in Table 4.
Artemisinin and ACT resistance has developed in the
Greater Mekong area of Southeast Asia (GMS) and has
continued to spread with increasing drug failure to
Table 2 Incidence of falciparum malaria in the study area (2018)
Samples collected No. of positive cases
Age (years) M F T M F T I (%)
≤5 43 56 99 24 20 44 44.44%
10–20 233 276 509 144 114 258 50.69%
≥20 126 132 258 47 33 80 31.01%
Total 402 464 866 215 167 382 44.11%
Abbreviations: M, males; T, total; F, females, I, incidence.
Table 3 Prevalence of falciparum malaria in the study area (2017/
2018)
Samples collected Positive samples
Age (years) M F T M F T I (%)
≤5 68 80 148 36 33 69 46.62%
10–20 320 372 692 192 164 356 51.45%
≥20 195 208 403 72 73 145 35.98%
Total 583 660 1,243 300 270 570 45.86%
Abbreviations: M, males; T, total; F, females, I, incidence.
Table 4 Chi-square analysis showing the relationship between
the incidence of falciparum malaria and age
Age
group
Positive
(%)
Negative
(%)
P-value
2017 ≤5 41 (58.57) 29 (41.43) 0.0665
10–20 108 (55.38) 87 (44.62)
≥20 63 (44.37) 79 (55.63)
2018 ≤5 44 (44.44) 55 (55.56) <0.0001
10–20 258 (50.69) 251 (49.31)
≥20 80 (31.01) 178 (68.992)
2017/
2018
≤5 69 (46.62) 79 (53.38) <0.0001
10–20 356 (51.44) 336 (48.55)
≥20 145 (35.98) 258 (64.02)
Notes: Values less than 0.05 are accepted as statistically significant. P-values are
from a chi-square test for proportions evaluating significant association of malaria
incidence with age. Incidence in 2018 and overall prevalence revealed this
significance.
Table 5 Prevalence of resistance genes in Ado-Odo/Ota, Ogun
state
Genes Genes No. of samples Positive samples
Blood Saliva Blood Saliva
Pfcrt 101 49 58 25
Pfmdr 46 30 16 8
PfK13 87 18 19 8
TOTAL 234 97 93 41
Olasehinde et al Dovepress
submit your manuscript | www.dovepress.com
DovePress
Infection and Drug Resistance 2019:121944
 
In
fe
ct
io
n 
an
d 
Dr
ug
 R
es
ist
an
ce
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
41
.2
03
.7
6.
25
2 
on
 1
7-
Ju
l-2
01
9
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
artemisinin combination therapies (ACTs); however,
across Africa, diverse non-synonymous K13 mutations
are being reported,27 and non-artemisinin resistance mar-
kers have been reported to be associated with ACT
response,14–19 and of recent to partial artemisinin resis-
tance but in the African region no study has attributed this
to K13 mutations.27 The strategy to contain this spread
thus warrants continued surveillance for these markers.
Point mutations in codons K76T and N86Y of Pfcrt and
Pfmdr-1 genes, respectively, as well as non-synonymous
mutations in Pfk13 genes, were targeted using PCR/nested
PCR-RFLP and sequenced for further analysis.
We identified the presence of Plasmodium falci-
parum chloroquine resistance transporter gene muta-
tions in 57.42% of 58 blood and 51.02% of 25 saliva
samples. Plasmodium falciparum multidrug resistance
gene mutations were detected in 34.78% of 16 blood
samples and 26.67% of eight saliva samples evaluated
Blood Saliva
M 6 5 4 3 2 1 6 5 4 3 2 1 N
300bp 
Plate 1 Gel electrophoresis result of the nested PCR product carried out on blood and saliva showing the Pfcrt genetic marker.
Abbreviations: M, molecular marker; bp, base pair.
0.00%
10.00%
20.00%
30.00%
40.00%
50.00%
60.00%
70.00%
Pfcrt Pfmdr PfK13
Blood
Saliva
Blood
Saliva
Incidence
Figure 1 Detection of P. falciparum resistance genes in blood and saliva.
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while Pfk13 gene was amplified in 21.84% of 19 blood
samples and 44.44% of eight saliva samples (Figure 1).
Sequencing analysis revealed no mutations in the K13
propeller domain, but various studies have shown that
the African K13-propeller mutations vary from those
found in Southeast Asia, and partial artemisinin resis-
tance in sub-Saharan Africa is developing.27–31 Several
independent mutations developed in the GMS in the
PfK13 propeller domain in the Southeast Asian
parasites; compared to those of African origin, these
genetic changes are less likely to be widespread due
to high transmission rates because they will be lost to
outcrossing; however, historically, resistance spreads
from Asia to Africa, where the higher propagation lim-
its elimination.
Mutations in Pfcrt K76T codon have commonlybeenas-
sociated with chloroquine resistance, while mutations in
Pfmdr-1 N86Y have been associated with both
M 1 2 3 4 5 6 7 8 9 10
300bp 
Plate 2 Gel electrophoresis result of the nested PCR of blood samples showing the Pfcrt genes.
M 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
265bp 
Plate 3 Gel electrophoresis result of the nested PCR on blood samples for Pfmdr1 genetic marker.
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chloroquine and amodiaquine resistance.14–19,31 High rates
of Pfcrt K76T were detected both in blood (47.89%) and
saliva (31.43%). This study presented results that attempt
to identify the presence of these gene polymorphisms in
saliva of humans with amplifiable malarial DNA using
nested PCR. This indicates that there is a possibility that
Plasmodium falciparum DNA is introduced into the
human saliva via an intracellular component; probably
through red blood cells that have been ruptured or DNA
from parasites trapped in macrophages.32 Hence,
challenges limiting the implementation of interventions
requiring country-wide screening for periodic malaria sur-
veillance, which is more effective for eradication of
malaria in other regions, can now be overcome using
saliva as a diagnostic fluid.
The incidence of Plasmodium falciparum malaria from
blood and saliva samples was established with the ampli-
fication of parasite genomic DNA from blood and saliva
samples, and point mutations in Pfcrt, Pfmdr-1 and
P. falciparum kelch propeller gene molecular marker
10 9 8 7 6 5 4 3 2 1 M
300bp 
300bp 
Plate 4 Gel electrophoresis result of the nested PCR product carried out on blood samples showing the K13 genetic marker.
1110 9 8 7 6 5 4 3 2 1 M
300bp 
Plate 5 Gel electrophoresis result of the nested PCR product carried out on saliva samples 1–11 showing the K13 genetic marker. Positive bands: Lane 2-3-7-8-9-10-11.
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were also detected. Despite the fact that human saliva
is mostly composed of water (98%), it contains lots of
electrolytes, proteins, and DNA, and it has been and is
currently being explored for the monitoring and diagnosis
of a wide variety of human diseases.12 This study reveals
the potential of saliva as a reliable diagnostics tool for
malaria detection and for mapping the spread of resistance
in this era of malaria eradication, hence making it easier to
overcome the reversal of decreasing transmission intensi-
ties in high malaria endemic regions such as Nigeria.
Prevailing factors such as fear of needles, risk of infec-
tions and perhaps traditional taboos may serve as a deterrent
to the successful diagnosis of malaria, especially in children
and among rural dwellers. However, most commonly used
malaria diagnoses for epidemiological surveys rely on the
use of blood drawn using needles, which inflicts pain on the
subject. Because young children are the most vulnerable to
infection and disease, they tend to constitute the de facto
sentinel group used for most malaria surveys. Their unwill-
ingness to participate in epidemiological survey owing to the
invasiveness of the diagnosis may grossly mitigate malaria
surveillance and control. This study showed high detection
rates comparable to blood diagnosis of molecular markers of
antimalarial resistance in the study area and reported the
absence C580Yor A578S SNP; the most frequent K13 allele
observed in Africa, associated with artemisinin resistance in
sub-Saharan African parasites and those found in Southeast
Asia.30,31
Conclusion
This research further analyzed the incidence and prevalence
of Plasmodium falciparum in Ado-Odo/Ota Local
Government area of Ogun State.2 The data provided reveal
high endemicity of falciparum malaria, the existence of
malaria resistance genes in the study area and the prospect
of saliva as a noninvasive “point-of-care” diagnostics tool.
It also confirms that subjects with lower age range are more
predisposed to falciparum malaria. The research achieved
and encourages systematic monitoring and surveillance of
malaria parasite infection caused by P. falciparum in the
study area which is in line with the WHO’s recommenda-
tion for effective routine monitoring.1 This will aid in
providing an updated guide in the use of ACTs.
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The authors report no conflicts of interest in this work.
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